Metabolomics-Based Elucidation of Therapeutic Mechanism of Luteolin Towards Autism in Children and Relevant Drug-Drug Interaction Risk

被引：0

作者：

Sun, Xingzhen ^{[1
]}

Li, Chaoyang ^{[1
]}

Wang, Xiang ^{[1
]}

Zhang, Rongrong ^{[1
]}

Hong, Ze ^{[1
]}

机构：

[1] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Gen Pediat, Huaian 223300, Jiangsu, Peoples R China

来源：

LATIN AMERICAN JOURNAL OF PHARMACY | 2015年 / 34卷 / 03期

关键词：

autism; drug safety; lutrolin; metabolomics; SPECTRUM DISORDERS; FORMULATION;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Limited understanding for pathogenetic autism spectrum disorders results in the limited drugs for these diseases. In the present study, metabolomics-based analysis method was employed to compare healthy volunteers (n = 10), autism children (n = 10), and luteolin-treated autism children (n = 10). The results showed that autism children exhibited higher long-chain fatty acid-carnitine conjugates than healthy volunteers, indicating the inhibition of fatty acids oxidative process in autism children. The treatment with luteolin significantly decreased the level of long-chain fatty acid-carnitine conjugates. The drug-drug interaction risk between luteolin and zidovudine was furtherly determined, and the results showed that luteolin did not affect the metabolism of these two drugs. In conclusion, metabolomics-based analysis of luteolin-treated autism patients showed that luteolin can reverse autism-induced inhibition of fatty acids metabolism. Additionally, this drug is relatively safe because of none of drug-drug interaction.

引用

页码：590 / 592

页数：3

共 50 条

[11] Metabolomics Analysis of Lasiodin-Related Potential Drug-Drug Interaction and Clinical Therapy of Lasiodin towards Nasopharyngeal Carcinoma
Wang, Cheng-Shi
Liu, Shou-Hou
Peng, Jin
Tang, Chen
Zhu, Wei-Guo
LATIN AMERICAN JOURNAL OF PHARMACY, 2015, 34 (05): : 1033 - 1035
[12] Prediction of drug-drug interaction caused by a mechanism-based CYP inhibitor in human
Kato, M
Higashida, A
Mitsui, T
Sakai, S
Aso, Y
DRUG METABOLISM REVIEWS, 2004, 36 : 285 - 285
[13] The valproic acid - dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevant
Prins, H.
Bollen, P.
Velthoven, K.
Rijnders, B.
de Vries-Sluijs, T.
van Nood, E.
Nouwen, J.
Bax, H.
Melo, M. de Mendonca
Verbon, A.
Burger, D.
Rokx, C.
HIV MEDICINE, 2019, 20 : 235 - 235
[14] PBPK Based Drug-Drug Interaction Risk Assessment of GSK2798745 with Simvastatin
Shaik, Jafar Sadik B.
Dung Nguyen
Sprecher, Dennis
Singh, Rajendra
Goyal, Navin
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S50 - S50
[15] Drug-Drug interaction extraction using a position and similarity fusion-based attention mechanism
Fatehifar, Mohsen
Karshenas, Hossein
JOURNAL OF BIOMEDICAL INFORMATICS, 2021, 115
[16] Drug-drug interaction extraction from biomedical texts based on multi-attention mechanism
Wu, Chengkun
Wang, Wei
Yang, Xi
Yang, Canqun
2021 8TH INTERNATIONAL CONFERENCE ON BIOINFORMATICS RESEARCH AND APPLICATIONS, ICBRA 2021, 2021, : 49 - 55
[17] Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies
Zhou, Honghui
Davis, Hugh M.
DRUG DISCOVERY TODAY, 2009, 14 (17-18) : 891 - 898
[18] Single Therapeutic Doses of Ubrogepant Are Not Associated with a Clinically Relevant Drug-Drug Interaction When Co-administered with Acetaminophen or Naproxen
Jakate, A.
Boinpally, R.
Butler, M.
Lu, K.
Womack, K.
McGeeney, D.
Periclou, A.
HEADACHE, 2019, 59 : 87 - 88
[19] AMDE: a novel attention-mechanism-based multidimensional feature encoder for drug-drug interaction prediction
Pang, Shanchen
Zhang, Ying
Song, Tao
Zhang, Xudong
Wang, Xun
Rodriguez-Paton, Alfonso
BRIEFINGS IN BIOINFORMATICS, 2022, 23 (01)
[20] Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment
Venkatakrishnan, K.
Obach, R. S.
Rostami-Hodjegan, A.
XENOBIOTICA, 2007, 37 (10-11) : 1225 - 1256

← 1 2 3 4 5 →